MedTrace Logo

AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM

NCT07347691 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 92

Last updated 2026-01-16

No results posted yet for this study

Summary

This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF.

Participants will be classified into two groups based on the AI analysis: a "High Risk" group and a "Low to Intermediate Risk" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.

Conditions

  • Embolic Stroke of Undetermined Source

Sponsors & Collaborators

  • DeepCardio Co., Ltd.

    collaborator UNKNOWN

  • Inha University Hospital

    lead OTHER

Principal Investigators

  • Yong-Soo Baek, MD, PhD · Inha University Hospital

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-19
Primary Completion
2027-05-31
Completion
2028-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07347691 on ClinicalTrials.gov